Home > Neurology > Mitochondria a promising druggable target for Alzheimer’s disease

Mitochondria a promising druggable target for Alzheimer’s disease


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
Communications Biology
Reuters Health - 13/01/2021 - New research further supports the concept that targeting mitochondria is a promising therapeutic strategy for Alzheimer's disease (AD). In a paper in Communications Biology, researchers report that a small-molecule inhibitor of mitochondrial complex I (MCI) known as CP2 reduces neurodegeneration and improves cognitive function in a translational mouse model of AD. "Pathways improved by CP2 treatment in APP/PS1 mice comprise major pathways essential for therapeutic efficacy in AD patients," report Dr. Eugenia Trushina with the Mayo Clinic, in Rochester, Minnesota, and colleagues. "AD is associated with early energy hypometabolism, synaptic and mitochondrial dysfunction, oxidative stress, inflammation, abnormal proteostasis and progressive neurodegeneration," they note in their paper. CP2 specifically inhibits the activity of MCI in human and mouse brain mitochondria. It penetrates the blood-brain barrier and accumulates in ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on